Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2018-04
ICR Author
Chau, Ian
Marsden,
Author
Muro, K
Cho, JY
Bodoky, G
Goswami, C
Chao, Y
Dos Santos, LV
Shimada, Y
Topuzov, E
Van Cutsem, E
Tabernero, J
Zalcberg, J
Chau, I
Cascinu, S
Cheng, R
Hsu, Y
Emig, M
Orlando, M
Fuchs, C
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background and aim REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young (≤ 45 and < 65 years) and elderly (≥ 65, ≥ 70, and ≥ 75 years) patients.Methods Patients were randomized 2:1 to receive ramucirumab plus best supportive care or placebo plus best supportive care (REGARD) or 1:1 to ramucirumab plus paclitaxel or placebo plus paclitaxel (RAINBOW). Subpopulation Treatment Effect Pattern Plots assessed efficacy and adverse events by age groups for ramucirumab versus placebo.Results The hazard ratios (HRs) for overall survival favored treatment with ramucirumab: REGARD ≤ 45 years (HR: 0.59, 95% confidence interval: 0.27-1.26), < 65 years (0.80, 0.59-1.10), ≥ 65 years (0.72, 0.48-1.08), ≥ 70 years (0.73, 0.44-1.23), and ≥ 75 years (0.59, 0.25-1.37); and RAINBOW ≤ 45 years (0.56, 0.33-0.93), < 65 years (0.78, 0.63-0.97), ≥ 65 years (0.88, 0.66-1.18), and ≥ 70 years (0.88, 0.60-1.28). The exception was elderly patients aged ≥ 75 years in RAINBOW (0.97, 0.47-2.01); however, patient numbers were low in this subgroup (n = 36). Similar findings were observed for progression-free survival, for which HRs numerically favored ramucirumab-treated patients. Adverse events (including grade ≥ 3) were not associated with age.Conclusions In comparison with placebo, ramucirumab conferred improvements in efficacy across age groups with a tolerable safety profile. Despite some limitations, these exploratory analyses support the use of ramucirumab in advanced gastric cancer, irrespective of age.
URI
https://repository.icr.ac.uk/handle/internal/1248
DOI
https://doi.org/10.1111/jgh.14007
Collections
  • Other ICR Research
Subject
Esophagogastric Junction
Humans
Adenocarcinoma
Stomach Neoplasms
Paclitaxel
Antineoplastic Combined Chemotherapy Protocols
Antibodies, Monoclonal
Neoplasm Staging
Treatment Outcome
Survival Rate
Double-Blind Method
Age Factors
Placebo Effect
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Randomized Controlled Trials as Topic
Clinical Trials, Phase III as Topic
Young Adult
Antibodies, Monoclonal, Humanized
Language
eng
Date accepted
2017-09-24
License start date
2018-04
Citation
Journal of gastroenterology and hepatology, 2018, 33 (4), pp. 814 - 824

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.